Gilead Sciences (GILD) SEC Filings: History & Chart

Gilead Sciences, Inc. (GILD)GILDGilead Sciences, Inc.

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.

Foster City, CA

17,000 employees

www.gilead.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Daniel O'Day

View full financials

Form	Filing Date	Accepted	Document
4	Jul 16, 2026	Jul 16, 2026	View filing
4	Jul 16, 2026	Jul 16, 2026	View filing
4	Jul 2, 2026	Jul 2, 2026	View filing
4	Jun 16, 2026	Jun 16, 2026	View filing
4	Jun 16, 2026	Jun 16, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
4	Jun 11, 2026	Jun 11, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	May 27, 2026	May 27, 2026	View filing
SC 13D/A	May 27, 2026	May 27, 2026	View filing
8-K	May 20, 2026	May 20, 2026	View filing
4	May 18, 2026	May 18, 2026	View filing
4	May 18, 2026	May 18, 2026	View filing
424B5	May 18, 2026	May 18, 2026	View filing
FWP	May 14, 2026	May 14, 2026	View filing
424B5	May 14, 2026	May 14, 2026	View filing
13F-HR	May 8, 2026	May 8, 2026	View filing
S-8	May 7, 2026	May 7, 2026	View filing
10-Q	May 7, 2026	May 7, 2026	View filing
8-K	May 7, 2026	May 7, 2026	View filing
4	May 4, 2026	May 4, 2026	View filing
4	May 4, 2026	May 4, 2026	View filing
4	May 4, 2026	May 4, 2026	View filing
4	May 4, 2026	May 4, 2026	View filing
4	May 4, 2026	May 4, 2026	View filing
4	May 4, 2026	May 4, 2026	View filing
4	May 4, 2026	May 4, 2026	View filing

SEC Filings

Recent Filings